Keyword: Juno Therapeutics
Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.
The data look competitive against Gilead’s Yescarta and Novartis’ Kymriah, leading analysts to predict Celgene will win FDA approval next year.
GlaxoSmithKline is joining forces with Lyell Immunopharma to boost the “fitness” of T cells treatments and improve their efficacy in solid tumors.
Ahead of Fierce 15 2019, we look back at how former winners are getting on.
FogPharma has hired Howard Stern, M.D., Ph.D., as its new chief scientific officer and Peter Fekkes, Ph.D., as VP of discovery bioscience.
Abeona fires CEO Carsten Thiel; MHRA CEO to leave in wake of Brexit; Lilly CMO to lead Brickell Bio; and Janssen's discovery head joins Incyte.
Allogene Therapeutics has nearly tripled its IPO goal, pricing the deal at the high end of the range and raising $288 million.
Alder hires Juno exec as CEO, Allergan brings in Abbott vet after investors demand change, and ResTORbio poaches Novartis researcher as clinical VP.
Nadim Ahmed said Celgene’s arm’s-length relationship with the biotech it bought for $7.2 billion three years ago led to a substandard filing.
Alder BioPharmaceuticals poached Juno’s COO to lead the company, as it preps to submit its migraine treatment for FDA approval and heavy competition.